Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids. C. Olgart, N. Frossard. #ERS Journals Ltd 2001. ABSTRACT: Nerve growth factor (NGF) has recently been suggested to contribute to inflammation and bronchial hyperresponsiveness in asthma. However, the cell types capable of NGF production in the human lung and airways, as well as the regulatory role of pro-inflammatory cytokines and of glucocorticoids on NGF secretion in pulmonary cells, have not been described.
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The neurotrophin nerve growth factor (NGF), in addition to its essential activity on nerve growth and survival [1, 2] , has recently been shown to function as an important inflammatory mediator. As evidenced from animal studies, NGF may contribute to the development of airway hyperresponsiveness [3 -5] and to an increased sensory and sympathetic innervation in the lung [4] , and it may evoke a phenotypic change of airway sensory neurones [4] . NGF also has a profound effect on cells of the immune system, many of which are critically important in the development of pulmonary inflammation and asthma-related symptoms. Hence, NGF increases the number of mast cells in peripheral tissue [6] and promotes mast cell differentiation [7] and survival [8] . In addition, NGF stimulates lymphocyte survival, proliferation and differentiation, and it enhances eosinophil survival and cytotoxicity [9] . Furthermore, NGF stimulates mast cell degranulation and mediator upregulation and release [1, 2, 10] ; it also enhances mediator release from various other inflammatory cells including basophils, eosinophils, neutrophils, macrophages, monocytes, and T-cells [1, 2, 9, 10] .
Apart from the lung and airways, a variety of cell sources have been studied and shown to synthesize and secrete NGF. Among these are cells of the immune system, including mast cells [11] , basophils, eosinophils, lymphocytes, monocytes, macrophages [1, 2, 9, 10] , as well as structural cells, such as fibroblasts and vascular smooth muscle cells of various origins [1, 2, 10] . However, information about NGF secretion from cells of the lung and airways is scanty.
In the present study, it has been hypothesized that the lung fibroblast may be a source of NGF in humans, and the regulation of NGF secretion by the pro-inflammatory cytokines and asthma-associated cytokines interleukin-1b (IL-1b) and tumour necrosis factor-a (TNF-a), and by the anti-inflammatory glucocorticoids has been studied.
Material and methods

Primary culture of human lung fibroblasts
Human lung-derived fibroblasts were obtained by the explant technique as previously described [12, 13] . Macroscopically normal human lung tissue was obtained at thoracotomy for bronchial carcinoma. Donors had no diagnosed allergy, pulmonary fibrosis or emphysema. One suffered from chronic obstructive pulmonary disease. The lung tissue from each donor was cut into fragments of 0.5 -2 mm 3 . Fragments were washed three times for 10 min each at 37uC with Eagle9s minimum essential medium (MEM), supplemented with 10% foetal bovine serum (FBS), MEM nonessential amino acids (1:100), L-glutamine (2 mM), penicillin (150 U?mL -1 ), streptomycin (150 mg?mL -1 ), gentamicin (25 mg?mL -1 ), amphotericin B (Fungizone1, 1 mg?mL -1 ) (all products from Gibco BRL, Cergy Pontoise, France). They were plated onto 35-mm tissue culture dishes (Costar, Cambridge, MA, USA), left for 10 min at room temperature to facilitate explant-adhesion, and subsequently cultured in the same medium at 37uC in a humidified air containing 5% carbon dioxide (CO 2 ), with the medium changed twice a week. The explants were removed after 2 -3 weeks. The cells grown out from the explants reached confluence within 1 -2 additional weeks. They were rinsed in Hank9s balanced salt solution (HBSS; Gibco BRL), trypsinized (Trypsine-ethylene diamine tetra-acetic acid (EDTA), Gibco BRL) for 3 min, centrifuged and resuspended in a medium that consisted of MEM supplemented with 10% FBS, MEM nonessential amino acids (1:100), L-glutamine (2 mM), penicillin (50 U?mL -1 ), streptomycin (50 mg?mL -1 ), and replated in 25 cm 2 flasks (Costar). The fibroblasts were subsequently split 1:4 at confluence and cultured in 75 cm 2 culture flasks (Costar) in a growth culture medium for the fibroblasts based on Dulbecco9s modified Eagle9s medium (DMEM/F12) (1:1) supplemented with 10% FBS, MEM nonessential amino acids (1:100), L-glutamine (2 mM), penicillin (50 U?mL -1 ), streptomycin (50 mg?mL -1 ), and insulin (5 mg?mL -1 ) (Lilly, Saint-Cloud, France). Cells were used for experimentation at the sixth or seventh passage. Cells were characterized as fibroblasts morphologically and by immunocytochemistry using a monoclonal mouse antihuman fibroblast antibody (5B5) that reacts with the b-subunit of prolyl-4-hydroxylase and the disulphide-isomerase (Dako, Trappes, France).
Experimental protocol
All experiments were performed on cells cultured in growth culture medium (DMEM/F12, 10% FBS) and starved (24 h In all experiments, cell supernatants were collected, kept on ice, centrifuged (4uC, 1,200 rpm, 5 min) and stored at -20uC until analysis. Cells were rinsed with HBSS, trypsinized, and counted in a Neubauer chamber to determine the total cell number. None of the cytokines or glucocorticoids had any effect on cell number. Cell viability was assessed using trypan blue dye exclusion. Experiments were performed in duplicates on cell material from at least 3 -5 different subjects.
Determination of nerve growth factor by enzymelinked immunosorbent assay
NGF secreted into the supernatant of control and treated fibroblasts was quantified with a commercial NGF-specific, highly sensitive, two-site enzyme-linked immunosorbent assay (ELISA)-kit according to the procedure indicated by the manufacturer (Promega, Madison, WI, USA). Briefly, 96-well immunoplates (MaxiSorp2, Nunc, Roskilde, Denmark) were coated with a polyclonal goat antihuman NGF antibody in a coating buffer (25 mM carbonate buffer, pH 9.7). After an overnight incubation at 4uC, plates were washed (20 mM Tris-HCl, 150 mM NaCl with 0.05% (v/v) Tween1-20) and incubated in a blocking buffer (supplied by the manufacturer) for 1 h. The supernatants and the standard recombinant human NGF dilutions in the low (0.3%) FBS-medium were incubated into the wells at 37uC in a humid chamber for at least 6 h, and washed. Rat monoclonal anti-NGF antibody (0.25 mg?mL -1 ) was added for an overnight incubation at 4uC, and washed. Antirat horseradish peroxidase-conjugated immunoglobulin-G (IgG) was added for a 2.5-h incubation period. Finally, the substrate (0.02% 3,39,5,59-tetramethylbenzidine and 0.01% hydrogen peroxidase) was added. The colorimetric reaction was stopped after 10 min with 1 M phosphoric acid, and the optical density was measured at 450 nm. All measurements were performed in duplicate. The technique allowed detection of NGF in the range of 3.9 -500 pg?mL -1 .
Expression of results and statistical analysis
Data were expressed as mean¡SEM either in pg NGF?mL -1 of culture supernatant, in pg NGF per 10 6 cells, or as a percentage of the control secretion (solvent). The tested populations followed the Gaussian distribution as tested by the method of Kolmogorov and Smirnov. Differences between groups were analysed with an unpaired, two-tailed t-test, or a oneway analysis of variance followed by Tukey-Kramer post-test when appropriate (GraphPad InStat, GraphPad Software, San Diego, CA, USA). Values of pv0.05 were considered significant.
Results
Cell density-related secretion of nerve growth factor NGF was secreted by lung fibroblasts in culture, as evidenced by NGF protein measurement in the cell supernatants. The cell density-dependent secretion pattern of NGF was first studied after various seeding densities (24, Effect of interleukin-1b and tumour necrosis factor-a on nerve growth factor secretion IL-1b (10 U?mL -1 ) induced a significant increase in NGF secretion from day 2 to day 8 of culture ( fig. 1a) . Maximal increase was observed at day 4 (2.9-fold) ( fig. 1a) , which was the time used for further experiments. Hence, a growth period of 4 days with a seeding density of 4,000 cells?mL -1 and a 24 h starvation period was chosen for all other experiments studying regulation of NGF secretion.
At day 4, a significant and time-dependent accumulation of NGF in the cell supernatant was observed 2 -24 h (6.9¡0.4 -13.2¡1.5 pg?mL -1 , pv0.05; fig. 1b) , and a stable NGF secretion was detected 24 -72 h ( fig. 1b) . IL-1b (10 U?mL -1 ) induced a significant enhancement of NGF secretion 8 -72 h, maximal at 8 and 24 h (2.2-fold; fig. 1b) .
IL-1b (0.3 -30 U?mL -1 ) and TNF-a (0.1 -30 ng?mL -1 ) both evoked a dose-dependent enhancement of NGF secretion at 24 h ( fig. 2) , with a maximal increase of 124% for IL-1b (30 U?mL -1 ) (EC502 .9 U?mL -1 ) and of 114% for TNF-a (30 ng?mL -1 ) (EC50~1.0 ng?mL -1 ). When combining both cytokines, IL-1b (0.1 -3 U?mL -1 ) and TNF-a (0.1 -1 ng?mL -1 ), an additive stimulatory effect was observed on NGF secretion ( fig. 3) . 
Effect of glucocorticoids on nerve growth factor secretion
The influence of glucocorticoids was studied on the constitutive and cytokine-stimulated NGF secretions. Budesonide (10 -7 M) significantly reduced the constitutive secretion of NGF by 42%, and attenuated the IL-1b (10 U?mL -1 )-and TNF-a (10 ng?mL -1 )-stimulated secretion of NGF by 70 and 62%, respectively ( fig. 4) . A similar effect was observed with dexamethasone (10 -6 M), with a reduction of the constitutive secretion by 39% (pv0.05), and of the IL1b (10 U?mL -1 )-stimulated secretion by 72% (pv0.001; not shown). Solvents had no effect on NGF secretion.
Discussion
The present study provides evidence that the human lung fibroblasts in culture constitutively produce NGF, whose levels are increased in response to the pro-inflammatory and asthma-associated cytokines IL-1b and TNF-a. In addition, the glucocorticoids induce a decrease in both the constitutive and the cytokine-stimulated NGF secretion by the lung fibroblasts.
The present study demonstrates that NGF may be secreted by cultured structural cells from the human lung, i.e. the pulmonary fibroblast. This finding is in agreement with studies showing that the human fibroblast from other origins, e.g. the skin, expresses and secretes NGF [14, 15] . However, a differential regulation of NGF expression has been reported in the same cell type, i.e. the fibroblast, derived from different tissues and at different stages of human development [15, 16] . For instance, CARTWRIGHT et al. [15] failed to detect any expression of NGF messenger ribonucleic acid (mRNA) in human embryonic lung fibroblasts, whereas expression was observed in postembryonic cutaneous fibroblasts. In the light of the present study, this suggests that different molecular mechanisms may regulate the human NGF gene expression or transcription during life or differentiation.
Interestingly, the present data show that NGF secretion by the human lung fibroblast is not constant during culture. It is high at the very early stages of cell culture, lowering with the increase in cell number, and reaching the lowest level after confluence. It was clearly demonstrated that this phenomenon is cell density-dependent, since decreasing secretion of NGF was obtained with cells seeded at increasing densities. This suggests that cells with a less established cell-tocell contact secrete more NGF than cells reaching confluence. These results are in full agreement with results from studies of NGF secretion in mouse astrocytes [17, 18] , epithelial cells [19] and human cutaneous fibroblasts [14] , where a cell densitydependent secretion has been reported.
In addition, the presented data provide evidence that the lung fibroblast secretes elevated levels of NGF when stimulated with the pro-inflammatory cytokines IL-1b and TNF-a. This increased secretion was time-and dose-dependent. These results are in agreement with data obtained from other structural cells, such as the rat sciatic nerve-derived fibroblasts [20] or the human skin fibroblasts [21] , where an enhanced NGF secretion is described in response to IL-1b and/or TNF-a. Additionally, it is shown that the combination of both IL-1b and TNF-a evokes an additive stimulatory effect on NGF secretion by human lung fibroblasts. This latter finding is not in full agreement with observations of a synergistic stimulatory effect of the combination of both cytokines on NGF secretion in Swiss 3T3 cells [22] . These diverse results may reflect different regulation and cross-talk of the signal transduction pathways stimulated by TNF-a and IL-1b in the different cell types. This is in agreement with the notion that the regulation of NGF secretion occurs in a cell-and tissue-specific manner, where a similar stimulus may have various effects in different cells [16] . Thus, when describing the control of NGF secretion by mediators of inflammation, direct testing of organ-and tissuespecific cells is prompted.
Excessive amounts of IL-1b and TNF-a have been implicated in the pathogenesis of a number of inflammatory conditions in the lung and airways, including asthma [23] . Furthermore, a number of cells involved in the inflammatory response, like the macrophages, mast cells or lymphocytes, are important sources of IL-1b and TNF-a. They are found in close proximity to the fibroblasts, and thus might be capable of stimulating NGF secretion in situ. Indeed, the doses of both cytokines used are within their biological range of action when expressed in airway inflammation [24] , as well as in other in vitro cell systems [20, 21] . Thus, the present results support a potentially important role for IL-1b and TNF-a to stimulate fibroblast secretion of NGF in pulmonary inflammation. This increases the list of potentially IL1b-and TNF-a-responsive genes in the lung. However, further studies are necessary to reveal whether IL-1b and TNF-a are involved in modulating lung and airway function through the stimulation of NGF production.
The enhanced secretion of NGF by the proinflammatory cytokines, IL-1b and TNF-a, suggests that elevated levels of NGF during pulmonary inflammation are likely. Recent studies have revealed elevated serum levels of NGF in subjects suffering from asthma, especially patients with severe allergic asthma [25] . Also, higher levels of NGF were detected in the bronchoalveolar lavage from asthmatics as compared with healthy individuals [10, 26] , as well as after allergen challenge in asthmatics [27] . NGF secretion most likely originates from lung and airway cells, like the fibroblast as a structural cell and/or the infiltrated inflammatory cells, such as the mast cells, eosinophils and/or lymphocytes, which are other potential sources of NGF in the lung and airways. The capacity of lung fibroblasts to produce elevated levels of NGF upon activation with IL-1b and TNF-a suggests that these cells may participate in the regulation of local inflammatory events. Hence, the fibroblast may not only be an end-target cell for the effect of mediators, but also a source of mediators capable of participating in further priming of surrounding inflammatory cells.
At present, little is known about the role of NGF in human lung and airways. NGF has been suggested to function as a paracrine survival factor for immune/ inflammatory cells, as well as for peripheral neurones [1, 2] . Indeed, recent studies have revealed that inflammatory/immune cells express the high-affinity cell surface receptor for NGF, tyrosine kinase receptor A (TrkA) [1, 2, 9 -11] , and that peripheral neurones express both the high-and low-affinity receptor for NGF, TrkA and a protein with the molecular weight of y75,000 kDa (p75), respectively [1, 2, 9, 10] . Inflammatory/immune cells as well as neurones, may thus be a target for NGF released in the airways. In addition, NGF has recently been reported to contribute to the development of airway hyperresponsiveness [3, 5] through a neurokinin-1 receptor-dependent mechanism. This neuronal "sensitization" may be a direct effect of NGF on the sensory nerves, or have an indirect component involving some inflammatory cells such as the mast cell [10, 11] or the T-helper 2 (Th2) cell [3, 10] . Hence, there is increasing evidence for a potential involvement of NGF in a variety of pathological conditions of the lung and airways.
As corticosteroids are known to have potent antiinflammatory effects and are clinically effective in suppressing inflammation in lung and airways, it was also determined whether budesonide and dexamethasone were capable of inhibiting secretion of NGF by human lung fibroblasts. The present study found that the constitutive NGF secretion was markedly decreased. In addition, the IL-1b-and TNF-a-stimulated NGF secretion was inhibited to the same low level. These findings are in agreement with studies showing that corticosteroids also inhibit the production of several other pro-inflammatory factors, such as IL-6, IL-8, IL-11, granulocyte macrophagecolony stimulating factor (GM-CSF), or regulated on activation, normal T-cell expressed and secreted (RANTES) from fibroblasts [28] . Although an inhibitory effect of glucocorticoids is reported on NGF expression by, for example, the murine fibroblast cell line L929 or rat sciatic nerve-derived fibroblasts [10, 29] , a stimulatory effect of glucocorticoids may be at hand in other cellular systems such as hippocampal neurones [1, 2] . The presented data suggest that glucocorticoids may inhibit excessive NGF secretion during inflammatory conditions, and that the human lung fibroblast might be an important therapeutic target for the anti-inflammatory action of glucocorticoids [28] . As reported in rat fibroblasts, the inhibitory effects of glucocorticoids on NGF secretion may involve a decreased NGF mRNA stability [29] , or a transcriptional repression, as suggested by LINDHOLM et al. [29] . This last mechanism might involve the interaction between glucocorticoids and the transcription factor activation protein-1 (AP-1), whose binding site is present in the promoter region of the human NGF gene [30] . However, this involvement has to be confirmed in human lung fibroblasts.
In conclusion, the present findings suggest that the human pulmonary fibroblasts may be an important source of nerve growth factor and that the proinflammatory and asthma-associated cytokines interleukin-1b and tumour necrosis factor-a, may enhance this nerve growth factor secretion. Taking into account the newly discovered effects of nerve growth factor linked to asthma-associated symptoms in animals [3, 5] , the fibroblast may, through stimulated nerve growth factor secretion, play an active role in airway inflammation. Furthermore, the anti-inflammatory glucocorticoids reduce the enhanced production of nerve growth factor. This study, thus, adds some new elements in the mechanism of action of the anti-inflammatory glucocorticoids, suppressing excessive nerve growth factor secretion from lung fibroblasts.
